Gel formulations containing catanionic vesicles composed of Alprenolol (cas 13655-52-2) and SDS: Effects of drug release and skin penetration on aggregate structure

Add time:09/25/2019    Source:sciencedirect.com

To fully utilize the extended contact time of gel formulations a novel formulation with drug containing catanionic aggregates offering prolonged drug release and skin penetration were investigated. This study aimed to further explore the drug release process from catanionic vesicles in gels.Catanionic vesicles were formed from Alprenolol (cas 13655-52-2) and sodium dodecyl sulphate. Physical gels composed of catanionic vesicles and a SoftCAT polymer were used as well as covalent Carbopol gels. Drug release was measured in vitro using a modified USP paddle method and the skin penetration was studied using dermatomized pig ear skin mounted in horizontal Ussing chambers. The aggregate structure was visualized with cryo-TEM during the drug release and skin penetration process.The study results show that catanionic vesicles are present in the formulations throughout the drug release process and during the clinically relevant skin application time. Hence, the decreased skin penetration rate stems from the prolonged release of drug substance from the gels. The rheological investigation shows that the gel structure of the physically cross-linked gels is maintained even as the drug substance is released and the gel volume is decreased. These findings indicate that the applicability of formulations like these is a future possibility.

We also recommend Trading Suppliers and Manufacturers of Alprenolol (cas 13655-52-2). Pls Click Website Link as below: cas 13655-52-2 suppliers

Prev:Regular paperAnalysis of the vasodilator action of Alprenolol (cas 13655-52-2)
Next:Microcalorimetric studies on the complex formation between cellobiohydrolase I (CBH I) from Trichoderma reesei and the (R)- and (S)-enantiomers of the β-receptor blocking agent Alprenolol (cas 13655-52-2))